2013-02-12
| Signal | Price | Bias | Subject | Owned |
|---|---|---|---|---|
| TOP PICK | $34.300 | CAUTIOUS | NORTH AMERICAN - LARGE | Yes |
Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.
Christine Poole
Managing Director,
GlobeInvest Capital Management